INC Research has made three management appointments to its team in Japan made to add to its clinical research and development capabilities in Asia.
The Raleigh-based clinical research organization’s Japan operations will be led by Hiromi Wakita, who was appointed General Manager and Clinical Director. Wakita brings nearly 30 years of clinical development expertise to his new role. He will work from INC’s Tokyo office, which manages all of its clinical operations, study start-up and regulatory activities for Japan.
Joining Wakita are Hiroshi Uoji, named Regulatory and Safety Director for Japan, and Shinichi Sato, Project Director, CNS Clinical Development in Japan. Uoji will lead INC’s consulting and clinical regulatory operations and supervise safety reporting functions in Japan. Sato will support central nervous system clinical development in the country. INC said the appointments give the CRO additional experience for conducting clinical research in Japan.
“As the world’s second largest pharmaceutical market, Japan offers huge potential in terms of advancing new medicines globally,” INC Executive Vice President, Asia/Pacific Garth Tierney said in a statement. “Having an experienced leadership team in place to better assist customers in gaining access to the world’s No. 2 ranked product market, while helping them navigate some of the cultural and regulatory differences in conducting research here, is key.”
Besides its Japan presence, INC Research has 20 offices in across the Asia/Pacific region.
